Study to Evaluate Safety and Toxicity of Polyphenon E (EGCG) in HIV-1-Infected Individuals

Inclusion Criteria: * HIV-infected individual as having at least two of the following in any combination obtained from 2 different samples: Positive HIV rapid test or ELISA and Western Blot; HIV RNA PCR\>10,000 copies/ml; positive HIV DNA PCR; neutralizable HIV p 24 antigen * Asymptomatic HIV-1 infected individuals who are either antiretroviral-naive or treatment-experienced. Subjects must have not been on ARV treatment for at least 12 weeks prior to enrollment and not have plans to start ARV treatment within 8 weeks of study initiation. * Male or female 18 to 65 years of age. Males must use barrier methods of contraception Females must be willing to abide by protocol specified methods to avoid becoming pregnant. Women of childbearing potential must use an adequate form of birth control determined by the investigator (e.g., oral contraceptives, double-barrier methods, hormonal injectable or implanted contraceptives, tubal ligation, or vasectomy). * HIV-1 RNA \>1,000 copies/mL at Screening. * In the opinion of the investigator, subject has a stable CD4+ T lymphocyte count while off ARV and 250 cells/mm3 at Screening. * Participants should have no clinically significant findings on screening evaluations (clinical, laboratory, or EKG). * Be able to comprehend and willing to sign an ICF. * Be able to comply with the protocol requirements. * Have life expectancy \> 6 months. * Laboratory values obtained during screening must be within normal limits or meet the following requireme…